Misonix to introduce OsteoSculpt for facial bone surgery at EACMFS Congress

Misonix, Inc. (Nasdaq: MSON), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has announced its attendance and exhibition at the 20th Congress of the European Association for Cranial-Maxillofacial Surgery (EACMFS), which was held recently in Bruges, Belgium.  The EACMFS is widely regarded as the premier educational event for maxillofacial surgery in Europe.  Misonix used this venue to introduce its new OsteoSculpt® Ultrasonic Bone Scalpel for use in facial bone surgery.

During the meeting, Dr. Roland Gilles and his colleagues from Hospital CHC Liege in Belgium presented their initial experience with 28 patients in orthognatic surgery, exclusively using the OsteoSculpt for bone cutting.  The team described the OsteoSculpt as safe and beneficial for orthognatic and maxillofacial bone surgery with an absence of nerve lesions while reducing blood loss and operative time.  Their detailed findings will be published in the proceedings of the Congress late in the year.

The OsteoSculpt was developed with the help of Dr. Gilles and other surgeon innovators.  It is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument without the safety issues often associated with rotary or reciprocating sharps. Another Misonix product, the BoneScalpel™ has been successfully used in thousands of bone surgeries for spinal decompression, spinal fusion, and scoliosis on a worldwide basis at many prestigious academic institutions.

"Misonix is excited by the expanded surgical use of our ultrasonic bone cutting technology," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "The clinical benefits for patient and surgeon over traditional means of bone surgery are evident.  This is another example of our commitment to state-of-the-art medical devices for use by the worldwide medical community working in cooperation with visionary thought leaders."

SOURCE Misonix, Inc.